The Chemical Genomics Centre

The Chemical Genomics Centre is an initiative of the Max Planck Society in cooperation with Merck, AstraZeneca, Boehringer Ingelheim, Bayer HealthCare and Bayer CropScience. It stands for high quality research in the area of Chemical Genomics and strong collaborations between industry and Max Planck research.

Based on the experience gained in the first funding period of the CGC (2005-2010) the concept of the second funding period of the CGC (2012-2017) was developed further and evolved to guarantee efficient research and collaboration among the participating groups. The scientific focus will remain to be on the chemical-biological analysis of biological phenomena through the use of small molecules.

 

 

greber

 

 grossmann

hennig start

Dr. B.Greber
Controlling stem cell fate decisions

 

Dr. T. N. Grossmann
Chemical Modification of Proteins

 

Dr. S. Hennig
Therapeutic Transcriptome Modifications

 

 laubinger start Wu Home  
Dr. S. Laubinger
Dr. S. LaubingerEpigenetic and small RNA-mediated gene regulation
Dr. Y. Wu
Chemical Biology of Membrane Trafficking
 

News

Two ERC Starting Grants awarded to Dr. Tom Grossmann and Dr. Yaowen Wu, respectively, January 2016
ERC Starting Grants to Dr. Tom Grossmann and Dr. Yaowen Wu

Tom Grossmann appointed new Professor in Chemistry at the VU University in Amsterdam
Tom Grossmann appointed new Professor in Chemistry at the VU University in Amsterdam

New Academic Drug Discivery Centers
Academic drug discovery centers: the economic and organizational sustainability of an emerging model

Merck KGaA and Lead Discovery Center Enter Collaboration for the Discovery of Anti-Cancer Compounds
european pharmaceutical review- Internetseite, 20. Januar 2011

Publications

List of Publications: Dr. B. Greber

List of Publications: Dr. T. N. Grossmann

List of Publications: Dr. S. Hennig

List of Publications: Dr. S. Laubinger

List of Publications: Dr. Y. Wu

unten